Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

Objectives To compare visual outcomes for low vision eyes (LVE) (20/200 Snellen) at the time of the first injection in a clinical practice setting. Methods Subgroup analysis of a multicenter national database of treatment- naïve eyes neovascular age related macular degeneration (nAMD) treated with a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Eye (London) 2024-12, Vol.38 (18), p.3450-3458
Hauptverfasser:	Puzo, Martín, Calvo-Perez, Pilar, Bartol-Puyal, Francisco, Sanchez-Monroy, Jorge, Martin-Pinardel, Ruben, Parrado-Carrillo, Alba, Moll-Udina, Aina, Bernal-Morales, Carolina, Sanchez-Vela, Laura, Sararols-Ramsay, Laura, Garay-Aramburu, Gonzaga, Arruabarrena, Carolina, García-Arumí, José, Abraldes, Maximino, Ruiz-Moreno, José María, Valldeperas, Xavier, Velázquez-Villoria, Daniel, Escobar-Barranco, José Juan, Gallego-Pinazo, Roberto, Figueroa, Marta S., Figueras-Roca, Marc, Barthelmes, Daniel, Gillies, Mark C., Casaroli-Marano, Ricardo P., Zarranz-Ventura, Javier
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/409 692/699/3161/3175 Acuity Age Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Bevacizumab - administration & dosage Bevacizumab - therapeutic use Blindness Databases, Factual Eye Female Humans Intravitreal Injections Laboratory Medicine Macular degeneration Male Medicine Medicine & Public Health Ophthalmology Patients Pharmaceutical Sciences/Technology Ranibizumab - administration & dosage Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - administration & dosage Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Receptors, Vascular Endothelial Growth Factor - therapeutic use Retina Retrospective Studies Spain Surgery Surgical Oncology Treatment Outcome Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors Vision Vision, Low - physiopathology Visual acuity Visual Acuity - physiology Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objectives To compare visual outcomes for low vision eyes (LVE) (20/200 Snellen) at the time of the first injection in a clinical practice setting. Methods Subgroup analysis of a multicenter national database of treatment- naïve eyes neovascular age related macular degeneration (nAMD) treated with anti-VEGF intravitreal injections divided into LVE and NLVE. Demographics, visual acuity (VA) at baseline and subsequent timepoints (12, 24, and 36 months), number of injections and visits data were collected using a validated web-based tool (Fight Retinal Blindness!). Results 3138 eyes were included, 705 LVE and 2433 NLVE. The LVE group had the greatest VA gain ( p
ISSN:	0950-222X 1476-5454 1476-5454
DOI:	10.1038/s41433-024-03322-8